A new family of enantioselective dirhodiumn(II) catalysts have been developed by Professor Michael P. Doyle at Trinity University using a rational approach employing molecular modeling and molecular orbital calculations. These catalysts show an extraordinary ability to enantioselectively catalyze a number of different organic reactions, allowing the convenient synthesis of a number of otherwise difficult to obtain enantioenriched materials. These catalysts are excellent candidates for commercialization, showing high yields, enantioselectivities, and turnover numbers, and a degree of ruggedness which permits catalyst recovery and reuse.
The specific aims for Phase I are: (1) To transfer the technology for catalyst production and use from the Doyle laboratories to Regis, and to prepare scaled up quantities of the catalysts Rh2(5R-MEPY)4 and Rh2(5S-MEPY)4 for use in application studies; (2) To use these catalysts to prepare selected products of cyclopropanation and intramolecular C-H insertion reactions; and (3) To use chiral chromatography as a tool to upgrade the products of these reactions from high enantioenrichment to enantiopurity. Phase I and Phase II grants will provide an opportunity to demonstrate the utility of the Doyle technology for the commercial production of highly useful enantiopure organic intermediates and pharmaceutical products.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43GM050029-01
Application #
3499032
Study Section
Special Emphasis Panel (ZRG7-SSS-6 (04))
Project Start
1993-08-01
Project End
1994-01-31
Budget Start
1993-08-01
Budget End
1994-01-31
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Regis Technologies, Inc.
Department
Type
DUNS #
City
Morton Grove
State
IL
Country
United States
Zip Code
60053